IPO

IPO art
Biotech

Evommune prices IPO amid government shutdown

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.
Gabrielle Masson Oct 30, 2025 12:34pm
IPO initial public offering

MapLight goes public via $250M IPO to fund Cobenfy competitor

Oct 27, 2025 6:45am
piggy bank surrounded by question marks

PE dealmaking, exit counts on the rise in Q3: PitchBook

Oct 20, 2025 5:05pm
IPO initial public offering markets raise financing

Inflammation biotech Evommune eyes IPO to fund dermatitis trials

Oct 10, 2025 6:35am
3D Rendering futuristic robot technology development artificial intelligence

MapLight illuminates $262M IPO plans to fund Cobenfy competitor

Oct 7, 2025 6:30am
IPO initial public offering Wall Street

Big Pharma-backed MapLight plots IPO

Sep 22, 2025 1:57pm